Bristol-Myers Squibb
Coverage of Bristol-Myers Squibb in the Nexus archive.
- AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors expressed disapproval of a proposed $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Sam Fazeli discussed the reaction to the deal.
- AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough
AstraZeneca and Bristol-Myers Squibb suggest that larger financial resources enable greater investment in potential blockbuster drugs. The article highlights the advantage of enlarged balance sheets in pharmaceutical development.
- AstraZeneca reported tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
AstraZeneca shares were declining while Bristol-Myers Squibb shares rose amid reported deal talks between the two pharmaceutical companies. Analysts are uncertain about the potential motivations for a partnership between the firms.
- BMS launches dual immunotherapy for metastatic melanoma
Bristol-Myers Squibb (BMS) has launched a dual immunotherapy treatment for metastatic melanoma, a type of advanced skin cancer. The therapy combines two immune checkpoint inhibitors to enhance anti-tumor responses.